Merck - 54 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits and dividends. The latest closing stock price for Merck as of April 16, 2024 is 125.06.
  • The all-time high Merck stock closing price was 131.95 on March 28, 2024.
  • The Merck 52-week high stock price is 133.10, which is 6.4% above the current share price.
  • The Merck 52-week low stock price is 99.14, which is 20.7% below the current share price.
  • The average Merck stock price for the last 52 weeks is 112.70.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 123.4214 112.5210 131.9500 112.5210 125.0600 15.45%
2023 105.8523 107.4426 115.2227 98.8253 108.3278 1.00%
2022 85.4108 72.0161 108.3900 68.8683 107.2589 49.38%
2021 71.1019 73.1993 84.0364 65.2519 71.8007 -2.92%
2020 71.8300 80.6641 80.6641 58.6556 73.9588 -7.21%
2019 70.9870 64.4954 80.4011 62.2172 79.7088 22.26%
2018 53.8756 46.5279 67.2116 44.4424 65.1950 40.00%
2017 50.5993 48.2938 54.2890 44.3929 46.5693 -1.47%
2016 45.3837 40.8182 51.7620 37.7926 47.2661 15.05%
2015 43.1867 43.0388 47.4337 37.3311 41.0827 -3.87%
2014 42.3366 36.1353 46.2178 36.1353 42.7378 16.95%
2013 33.2073 29.1013 36.5442 28.7564 36.5442 26.80%
2012 28.4246 25.8812 33.4344 25.2122 28.8198 13.13%
2011 22.4738 23.2574 25.6109 19.6697 25.4758 9.54%
2010 22.7081 22.9010 25.3885 19.8924 23.2574 2.86%
2009 17.8515 18.1934 23.5136 12.5207 22.6102 26.73%
2008 21.1665 32.2262 34.0125 13.6312 17.8413 -45.34%
2007 28.0361 23.9934 34.1361 23.4047 32.6419 37.36%
2006 20.4694 17.1508 24.9746 17.1508 23.7644 42.66%
2005 15.6154 15.5736 17.6113 13.3646 16.6586 4.04%
2004 20.4429 22.5743 23.5708 12.7780 16.0121 -27.76%
2003 24.2451 25.7288 28.3049 19.3158 22.1665 -11.35%
2002 23.5307 25.7359 27.8760 17.0187 25.0045 -1.26%
2001 30.2277 39.1716 39.1716 24.6205 25.3225 -35.79%
2000 30.7967 27.9979 39.9087 22.4384 39.4370 41.78%
1999 30.0626 30.5318 35.3326 25.0275 27.8157 -7.48%
1998 26.0417 21.5939 32.3458 20.6507 30.0630 41.32%
1997 18.7734 15.7384 21.5337 15.7384 21.2728 35.61%
1996 13.2531 12.3928 16.5160 11.0490 15.6872 23.92%
1995 9.4278 7.2165 12.9001 6.8630 12.6590 76.57%
1994 6.1459 6.4022 7.4045 5.1995 7.1694 14.82%
1993 6.2712 7.7355 7.7355 5.1351 6.2442 -18.35%
1992 8.4657 9.5871 9.7306 7.2112 7.6474 -20.29%
1991 6.8439 5.0579 9.5940 4.6482 9.5940 88.88%
1990 4.4066 4.3325 5.0794 3.7224 5.0794 18.95%
1989 3.8355 3.0795 4.3828 3.0795 4.2703 37.47%
1988 2.9047 2.8749 3.1793 2.5449 3.1064 12.05%
1987 2.9404 2.2038 3.8042 2.2038 2.7723 27.96%
1986 1.6722 1.2069 2.2650 1.1839 2.1666 80.84%
1985 0.9603 0.8145 1.1981 0.7904 1.1981 45.74%
1984 0.7750 0.7904 0.8483 0.6974 0.8221 4.01%
1983 0.7953 0.7346 0.9117 0.7171 0.7904 6.81%
1982 0.6723 0.7477 0.7674 0.5619 0.7400 -0.16%
1981 0.7602 0.7521 0.8953 0.6690 0.7412 0.00%
1980 0.6362 0.6187 0.7412 0.5138 0.7412 17.32%
1979 0.5905 0.5936 0.6460 0.5476 0.6318 6.83%
1978 0.5036 0.4689 0.6046 0.4209 0.5914 21.84%
1977 0.4911 0.5859 0.5859 0.4406 0.4854 -18.52%
1976 0.6254 0.6089 0.7029 0.5510 0.5957 -1.63%
1975 0.6513 0.5881 0.7477 0.5138 0.6056 4.32%
1974 0.6285 0.7029 0.7488 0.4285 0.5805 -17.80%
1973 0.7812 0.7915 0.8789 0.6799 0.7062 -9.39%
1972 0.6680 0.5477 0.7827 0.5477 0.7794 43.75%
1971 0.4635 0.4154 0.5717 0.4154 0.5422 25.25%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $316.781B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $709.526B 118.15
Novo Nordisk (NVO) Denmark $553.986B 45.64
Johnson & Johnson (JNJ) United States $348.093B 13.81
AbbVie (ABBV) United States $287.801B 14.63
AstraZeneca (AZN) United Kingdom $211.650B 18.75
Novartis AG (NVS) Switzerland $197.547B 13.69
Pfizer (PFE) United States $145.471B 14.04
Sanofi (SNY) $115.856B 10.43
Innoviva (INVA) United States $0.915B 6.46